The urinary excretion of 6-sulphatoxymelatonin (aMT6s) from 2400 to 0600 h was significantly increased following the treatment of ten normal volunteers with a phospho diesterase inhibitor (rolipram 1 mg 8 h for 24 h). The urinary excretion of the metabolite from 0600 to 1200 h was significantly reduced after treatment with rolipram.
Get full access to this article
View all access options for this article.
References
1.
Arendt J.Bojkowski C.Franey C.Wright J.Marks V.1985Immunoassay of 6-hydroxymelatonin sulphate in human plasma and urine: abolition of the urinary 24 hours rhythm with atenolol. Journal of Clinical Endocrinology and Metabolism60: 1166-1173
2.
Axelrod J.Shein H.M.Wurtman R.J.1969Stimulation of C14 tryptophan by noradrenaline in rat pineal in organ culture. Proceedings of the National Academy of Sciences USA69: 2547-2550
3.
Berg G.R.Klein D.C.1971Pineal gland in organ culture II. Role of adenosine 3,5, monophosphate in the regulation of radiolabelled melatonin production . Endocrinology89: 453-461
4.
Checkley S.A.Thompson C.Burton S.Franey C.Arendt J.1985Clinical studies of the effect of (+) and (-) oxaprotiline upon noradrenaline uptake. Psychopharmacology87: 116-118
5.
Cowen P.J.Fraser S.Sammons N.Green A.R.1983Atenolol reduces plasma melatonin concentrations in man . British Journal of Clinical Pharmacology15: 579-581
6.
Franey C.Aldhous M.Burton S.Checkley S.Arendt J.1986Acute treatment with desipramine stimulates melatonin and 6-sulphatoxy melatonin production in man. British Journal of Clinical Pharmacology22: 73-79
7.
Jones R.L.McGreer P.L.Greiner A.C.1969Metabolism of exogenous melatonin in schizophrenic and non-schizophrenic volunteers. Clinica Chimica Acta (Amsterdam) 26: 281-285
8.
Kehr W.Debus G.1983Rolipram, a potential antidepressant: effect on catecholamine (CA) and 5-hydroxytryptamine (5-HT) metabolism m rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology324 (Supplement) R23 abstract 92
9.
Klein D.C.1985Photoneural regulation of the mammalian pineal gland . In: Photoperiodism melatonin and the pineal. (ed. Short R V), pp. 38-51. CIBA Foundation Symposium 117 Pitman , London
10.
Klein D.C.Weller J.L.1970Indole metabolism in the pineal gland: a circadian rhythm in N-acetyltransferase. Science (Washington DC) 169: 1093-1095
11.
Klein D.C.Berg G.R.Weller J.1970Melatonin synthesis: adenosine 3,5-monophosphate and norepinephrine stimulate N-acetyltransferase. Science168: 979-980
12.
Lewy A.J.1984Human melatonin secretion: a marker for adrenergic function . In: Neurobiology of mood disorders (eds Post R MBallenger J C), pp. 207-214. Williams and Wilkins, Baltimore
13.
Schwabe U.Miyake M.Ohga Y.Daly J.W.19764-(3-cyclopentyloxy-4-methoxy)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3,5, monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Molecular Pharmacology12: 900-910
14.
Strada S.Klein D.C.Weller J.L.Weis B.1972Norepinephrine stimulation of cyclic adenosine monophosphate in cultured pineal gland. Endocrinology90: 1470-1475
15.
Sugden D.Namboodiri M A AKlein D.C.Pierce J.E.Grady R.K. Jr Mefford I.1985Ovine pineal alpha-adrenoceptors: characterization and evidence for a functional role in the regulation of serum melatonin. Endocrinology116: 1960-1967
16.
Vaughan G.M.Pelham R.W.Pang S.F. et al. 1976Nocturnal elevation of plasma melatonin and urinary 5-hydroxymdoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. Journal of Clinical Endocrinology and Metabolism42: 752-764
17.
Wachtel H.1982Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3,5, monophosphate phosphodiesterase inhibitors. Psychopharmacology77: 309-316
18.
Wirz-Justice A.Campbell I.C.1982Antidepressant drugs can slow or dissociate circadian rhythms . Experientia38: 1301-1309
19.
Zatz M.Kebabian J.Romero J.A.Lefkowtiz R.J.Axelrod J.1976Pineal beta-adrenergic receptor: correlation of binding of 1-alprenolol with stimulation of adenylate cyclase. Journal of Pharmacology and Experimental Therapeutics196: 714-722
